Pertuzumab/Trastuzumab Biosimilar (Henlius Biotech)

N/A

Report date: 2026/05/25 20:02:40

Base Information

Drug NamePertuzumab/Trastuzumab Biosimilar (Henlius Biotech)
Drug Alias NameHLX319HLX-319
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonists
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsBreast Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsYes
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShanghai Henlius Biotech Inc
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Henlius Biotech Inc
Inactive CompaniesN/A
Active IndicationsBreast Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A